AdipoGen Life Sciences

Linifanib

Product Code:
 
SYN-1002
Product Group:
 
Inhibitors and Activators
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
Short term: +4°C. Long term +4°C
1 / 1
Chemical Structure
❮❯

Chemical Structure

No additional charges, what you see is what you pay! *

CodeSizePrice
SYN-1002-M100100 mgEnquire
Quantity:
SYN-1002-M0011 mg£105.00
Quantity:
SYN-1002-M0055 mg£152.00
Quantity:
SYN-1002-M01010 mg£245.00
Quantity:
SYN-1002-M05050 mg£655.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Related Products
  • Show All

Further Information

Alternate Names/Synonyms:
ABT-869; AL39324; RG-3635
Appearance:
Solid.
CAS:
796967-16-3
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
InChiKey:
MPVGZUGXCQEXTM-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 796967-16-3. Formula: C21H18FN5O. MW: 375.4. Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer. Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3beta phosphorylation and maybe influencial in AML therapy.
Molecular Formula:
C21H18FN5O
Molecular Weight:
375.4
Package Type:
Plastic Vial
Product Description:
Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer. Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3beta phosphorylation and maybe influencial in AML therapy.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor: Y. Dai, et al.; J. Med. Chem. 50, 1584 (2007)